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Abstract
Genetic aberrations are crucial in renal tumor progression. In this study, we describe loss of heterozygosity (LOH)
and DNA–copy number abnormalities in clear cell renal cell carcinoma (cc-RCC) discovered by genome-wide single
nucleotide polymorphism (SNP) arrays. Genomic DNA from tumor and normal tissue of 22 human cc-RCCs was
analyzed on the Affymetrix GeneChip Human Mapping 10K Array. The array data were validated by quantitative
polymerase chain reaction and immunohistochemistry. Reduced DNA copy numbers were detected on chromo-
somal arm 3p in 91%, on chromosome 9 in 32%, and on chromosomal arm 14q in 36% of the tumors. Gains were
detected on chromosomal arm 5q in 45% and on chromosome 7 in 32% of the tumors. Copy number abnormal-
ities were found not only in FHIT and VHL loci, known to be involved in renal carcinogenesis, but also in regions
containing putative new tumor suppressor genes or oncogenes. In addition, microdeletions were detected on
chromosomes 1 and 6 in genes with unknown impact on renal carcinogenesis. In validation experiments,
abnormal protein expression of FOXP1 (on 3p) was found in 90% of tumors (concordance with SNP array data
in 85%). As assessed by quantitative polymerase chain reaction, PARK2 and PACRG were down-regulated in
57% and 100%, respectively, and CSF1R was up-regulated in 69% of the cc-RCC cases (concordance with SNP
array data in 57%, 33%, and 38%). Genome-wide SNP array analysis not only confirmed previously described large
chromosomal aberrations but also detected novel microdeletions in genes potentially involved in tumor genesis
of cc-RCC.
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Introduction
Renal cell carcinoma (RCC) is the most common tumor of the adult
kidney and represents approximately 2% of all adult malignancies.
Histopathologically, RCC can be subdivided in clear cell carcinomas
(approximately 80% of sporadic RCC) and a few other subtypes such
as papillary, chromophobe, and medullary RCC. The molecular ge-
netics of RCC have been studied intensively. More than any other
group of epithelial malignancies, some subtypes of adult RCC, such
as clear cell renal cell carcinoma (cc-RCC) or papillary RCC, are
readily distinguishable by gene expression profiling [1,2].
Abbreviations: cc-RCC, clear cell renal cell carcinoma; DNA-CNA, DNA–copy num-
ber aberration/abnormality; LOH, loss of heterozygosity; SAS, single allele score; SNP,
single nucleotide polymorphism; TSG, tumor suppressor gene
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Genetic events seem to play an important role in the pathogenesis
of primary sporadic cc-RCC. Inactivation of tumor suppressor genes
(TSGs) on chromosome 3p is the most common event in cc-RCC
and loss of heterozygosity (LOH) at 3p12, 3p14.2, 3p21.3, and
3p25 was often described [3–5].
The von Hippel-Lindau (VHL) gene, located at 3p25-p26, shows
intragenic mutations in approximately 50% to 57% and LOH in
approximately 80% to 90% of the cases of sporadic cc-RCC [6,7]. It
seems that mutations of VHL alone are not sufficient to cause malig-
nant disease but that additional mutations of other genes are required
for malignant tumor growth. Hitherto, it is unclear if cc-RCC without
VHL mutations takes other routes of VHL inactivation or alternative
non-VHL tumor pathways [3,4]. It was demonstrated that LOH at
3p in cc-RCC occurs in association with allelic loss on one or more
chromosomal arms such as 6p, 8p, 9pq, and 14q [8].
In papillary renal tumors, additional regions of LOH were ob-
served on chromosomes 6p, 9pq, 11q, 14q, and 21q, suggesting that
TSGs localized on chromosomes 6p, 9pq, and 14q are involved in
development of both papillary and nonpapillary renal cancer [8].
Reports concerning the prognostic relevance of chromosomal
aberrations in RCC are conflicting. VHL status in RCC has no asso-
ciation with tumor grade and stage [4]. Thrash-Bingham et al. [8]
found no correlation between LOH and allelic imbalances with
tumor size, nodal involvement, metastasis, or nuclear grade in RCC.
No correlation was found between 3p loss and tumor size, nodal in-
volvement, tumor grade, or metastasis in RCC, but metastasizing
tumors showed more aberrations than nonmetastasizing tumors [9],
and patients with increased DNA losses showed a shorter time to re-
currence than patients with few DNA losses [10].
Conversely, a positive correlation between allelic loss at chromo-
some 14q, especially 14q24-q31, 14q31-q32, and a poor prognosis
were described [11–13]. Patients with 3p loss and gain at 5q22.3,
due to an unbalanced translocation between these chromosomes,
had a significantly better disease-specific survival [14].
It is certain that genetic aberrations play an important role in
RCC, but it is still unclear which genetic events are involved in tu-
mor initiation and progression. There are obviously many, still un-
known, small mutations that could be important for carcinogenesis
and progression in RCC.
Historically, two key techniques were used to detect DNA copy
number variations in DNA samples: comparative genomic hybridiza-
tion (CGH) and LOH analysis. The array CGH technique can use
bacterial artificial chromosome, cDNA, and oligonucleotides, and it
is more sensitive because its higher resolution could be studied.
Hybridization to single nucleotide polymorphism (SNP) arrays is
an efficient method to simultaneously detect genome-wide LOH and
DNA–copy number aberration (DNA-CNA) [15,16].
To the best of our knowledge, only one study on RCC applying
high-resolution techniques on only three cases exists up to date [17].
In the present investigation, we studied a representative cohort of
patients (n = 22) with cc-RCC with clinicopathological correlations
to uncover regions of LOH and DNA-CNA affecting genes in the
whole genome.
Materials and Methods
Patients
Fresh frozen material from 22 primary cc-RCC and matched nor-
mal kidney tissues were collected at the Department of Urology of
the University of Technology, Dresden, between 1994 and 2001.
All samples were obtained directly after surgery. Fresh material was
snap-frozen and stored in liquid nitrogen until further processing.
Each sample was evaluated microscopically to ensure a pure popula-
tion of tumor and normal cells, respectively. The average of normal
cell contamination in tumors was <5%. The normal tissue samples
showed no tumor cell contamination. Histological typing of tumors
was performed in accordance to the UICC classification (1997).
The clinicopathological characteristics and the follow up data of
the patients are given in Table 1.
Signed informed consent was obtained from all patients in this study.
All procedures were reviewed by the ethical committee of the Uni-
versity of Technology, Dresden (no. 195092004).
DNA Preparation
Genomic DNA of both tumor and normal tissue was extracted from
80 to 100 frozen sections of 10-μm thickness (corresponding to 30–
40 mg of tissue) with the Invisorb Spin Tissue Kit (Invitek GmbH,
Berlin, Germany) according to the manufacturer’s instructions.
GeneChip Human Mapping 10K Array
The tumor and normal tissue samples were analyzed on the Affy-
metrix GeneChip Human Mapping 10K Array Xba 131 (Affymetrix,
Santa Clara, CA). The DNA for hybridization was prepared accord-
ing to the Affymetrix Mapping Assay protocol. Briefly, 250 ng of
DNA was digested with the restriction enzyme XbaI; fragments were
ligated to an adaptor and amplified using a universal polymerase
chain reaction (PCR) primer in six PCR reactions in parallel. Frag-
ment sizes were confirmed by electrophoresis on 2% agarose gel,
and the PCR products were pooled and purified using the MinElute
96 UF PCR Purification Plate (Qiagen, Valencia, CA).
The fragmented and labeled DNA was hybridized to the GeneChip
Human Mapping 10K Array Xba 131 overnight at 48°C. The arrays
were washed, stained, and scanned according to Affymetrix standard
Table 1. Clinicopathological Characteristics.
Case ID Age at Diagnosis
(years)
Sex
(M/F)
Grading pT Stage pN Stage Metastasis Status
4 51 M G3 pT2 pN0 Pulmonary NA
7 80 F G1 pT3b pN1 No NA
26 66 F G3 pT2 pN2 Pulmonary NA
28 64 F G2 pT2 pN2 Other* DOD
31 61 F G2 pT3b pN0 No NA
44 60 F G2 pT3b pN0 Pulmonary + other DOD
65 64 M G1 pT1 pN0 Other DOD
69 51 M G2 pT2 pN0 Pulmonary + other DOD
81 56 M G2 pT2 pN0 Other NA
88 39 M G2 pT2 pNx No NA
122 41 M G2 pT3b pN0 Pulmonary + other DOD
126 71 M G2 pT1 pN0 Pulmonary + other DOD
132 66 M G3 pT3b pN1 Pulmonary + other DOD
135 61 M G2 pT1 pN1 Other DOD
139 57 F G2 pT1 pNx No ANED
154 52 F G2 pT1 pN0 Other DOD
163 62 M G2 pT1 pNx No DAD
167 35 F G2 pT4 pN0 Pulmonary ANED
178 63 F G2 pT1 pNx No NA
182 77 M G3 pT2 pNx Other DOD
195 70 M G2 pT1 pN0 Other DOD
201 51 M G3 pT1 pN2 Other DOD
ANED indicates alive no evidence of disease; DAD, dead of another disease; DOD, dead of disease;
NA, not available.
*Other: cerebral, mediastinal, pancreas, adrenal glands, liver, bones, or glandula parotis metastasis.
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protocols using the Affymetrix GeneChip Fluidic Station and the
Agilent GeneArray 2500 Scanner (Agilent Technologies, Palo Alto, CA).
Array Scan and Data Collection
Image analysis was performed using the Affymetrix GeneChip
Analysis Software MAS 5.0, and results were assessed using GeneChip
Genotyping Analysis Software Version 4.0 (Affymetrix). The LOH re-
gions were detected and demarcated with the Chromosome Copy
Number Analysis Tool software version 3.0 (CNAT 3.0) from Affyme-
trix. The concordance check was performed between tumor and nor-
mal tissue of the same specimen. The overall SNP call rate was
determined by the software as the number of SNPs assigned AA,
BB, or AB divided by the total number of SNPs on the microarray.
Results containing information about the identity of each SNP and
its chromosomal location were exported to Excel worksheets for fur-
ther analysis.
Data Analysis
Raw intensity data were retrieved in CEL files and analyzed using
a self-developed analysis algorithm as described previously [18]. In
brief, for copy number analysis, individual probe intensities were
locally intensity corrected and merged in intensity values for each
probe set. Tumor and normal tissue values were combined to ratios,
and the log2 of these ratios were exported for further analysis. For the
determination of the allelic configuration of each individual SNP,
the intensity distribution between the two alleles was compared. A
biallelic SNP, which is characterized by the same intensity for both
alleles, is expressed in (single allele) scores of 0.0. LOH and therefore
SNPs, which feature only a single allele with noteworthy intensity,
result in single allele scores (SAS) of 1.0. LOH was assumed when
the same normal tissue biallelic marker was found to be monoallelic
in the tumor tissue. In three cases, we were not able to generate
analyzable DNA profiles of normal tissues (#4, #7, and #139) due
to lack or low amount of starting material. For these cases, we looked
at the SAS values only for the tumor DNA and stated LOH by
judging the local absence of biallelic markers. For the generation of
copy number profiles for these cases, an average of all normal tissue-
derived intensities was used as a reference.
For the detection of microdeletions, we considered three affected
SNP in a row as the threshold.
Quantitative PCR
To validate the microarray data by quantitative PCR (qPCR), 16
of 22 tumor samples and matched normal tissue were available.
Total RNA was isolated from tissue samples according to the
manufacturer’s instructions (Invisorb Spin Cell/Tissue RNA Mini
Kit; Invitek, Berlin, Germany) and was transcribed into cDNA using
random hexamer primers (Amersham, Freiburg, Germany) and the
SuperScript II Reverse Transcriptase (Invitrogen, Karlsruhe, Ger-
many). Transcript levels of three selected genes (CSF1R, PACRG,
and PARK2) and the reference gene PPIA (peptidyl-prolyl cis–trans
isomerase A) were determined by qPCR on the LightCycler 480 in-
strument (Roche, Mannheim, Germany) using commercially avail-
able assays on demand (HS_00234622-m1, HS_00247755-m1,
and HS_00330069-m1) and the TaqMan Gene Expression Master
Mix (all from Applied Biosystems, Darmstadt, Germany).
Using the ΔΔCT method [19], expression levels of the genes of
interest were normalized to those of the internal reference gene PPIA,
which was detected in all samples (crossing point, <36). As threshold
for altered expression in tumor samples, we considered a twofold up-
or down-regulation compared with the expression in matched normal
tissues. Absence of expression of target gene in tumor tissue (crossing
point, ≥36) combined with gene expression in matched normal tissue
was considered as a complete loss. In contrast, absence of expression
of target gene in normal tissues accompanied by detectable target
gene expression in the matched tumor sample was considered as a
tumor-associated up-regulation. If the target gene expression was
under the detection limit (crossing point, <36) in both, tumor and
nonmalignant tissue, the sample pair was excluded from analysis for
the corresponding target gene.
Immunohistochemistry
Immunohistochemical staining for FOXP1 was performed using
tissue microarrays (TMAs) from formalin-fixed, paraffin-embedded
archival material. The TMA contains one to five cores each of tumor
and normal tissue from 20 of the patients analyzed by SNP micro-
arrays. The sections were deparaffinized, and the antigen retrieval was
done at 95°C with sodium citrate buffer (pH = 6.0). The sections
were immersed in 0.3% hydrogen peroxide for 10 minutes to block
endogenous peroxidase activity. Thereafter, the slides were incubated
overnight at 4°C with a polyclonal antibody (1:250) against FOXP1
(Clone ab16645; Abcam, Cambridge, UK), followed by incubation
with the EnVision Plus detection system (DAKO, Copenhagen,
Denmark). Staining was visualized with diaminobenzidine solution
followed by counterstaining with hematoxylin.
The normal kidney tissue was first examined to establish the nor-
mal FOXP1 staining in renal tissue. Then, tumor cores were ex-
amined, and nuclear, membranous, and cytoplasmic expression was
evaluated. The FOXP1 expression was scored using the following
system: 0% to 10% positive cells = 0; >10% to 30% positive cells =
1; >30% to 70% positive cells = 2; >70% positive cells = 3. Mem-
branous expression of FOXP1 or concomitant nuclear and cytoplas-
mic expression of FOXP1 in tumor cells was considered as aberrant.
Results
A total of 22 cc-RCC and paired normal tissues were screened by
high-resolution SNP-Chip analysis.
The median age at diagnosis was 61 years. Two patients showed
metastasis at the time of diagnosis (#25 and #135). Follow-up data
were available from 15 patients. The median time to tumor progres-
sion was approximately 12 months. Case 167 presented one solitary
pulmonary metastasis that was removed operatively; thereafter, no
further metastases were detected (Table 1).
The most common type of alteration we observed in all patients
was the loss of one allele, which led to LOH (68 events). The gain
of chromosomal regions was noted less frequently (25 events). All
detected larger genomic imbalances are summarized graphically in
Figure 1. Sporadically, we detected LOH that was not accompanied
by a copy number loss (three events: on chromosomes 3, 6, and 7).
A representative example of DNA-CNA and LOH profile is
shown for case 154 in Figure 2, revealing LOH on chromosomes 3,
6, and 8, each accompanied by a copy number loss and a gain of
copy of chromosome 7, which did not change the allelic balance.
Frequent Large Aberrations
In 20 (91%) of 22 cases, LOH due to the loss of one copy on 3p
harboring the VHL gene was found. The two cases without alterations
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Figure 1. Graphical representation of chromosomal imbalances detected in genomes of patients with cc-RCC. Losses associated with
LOH are indicated as red lines and green lines denote regions of copy number gains. Orange line points to a single occasion where copy
number loss was not associated with LOH and blue lines indicate regions with LOH without copy number loss. The most frequent
alterations are LOH due to hemizygous deletion on chromosomes/arms 3p, 9, and 14 and gains on 5q and 7. Patient IDs from left
to right: 122, 126, 132, 135, 139, 154, 163, 167, 178, 182, 195, 201, 26, 28, 31, 44, 4, 65, 69, 7, 81, and 88.
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on 3p had very few copy number alterations in general. Ten tumors
(45%) showed a gain on the chromosomal arm 5q. The corresponding
minimal overlapping region comprised 5q23.3.-5qter. Other frequent
chromosomal alterations were as follows: 6q− (27%), 9− (32%), 7q+
(32%), and 14q− (36%). A complete list of large aberrations is pro-
vided in Table 2.
No relation was found between the common occurrence of 3p loss
and gains on chromosome 5 concerning a better disease-specific sur-
vival of the patients. In addition, no correlation between individual
chromosomal aberrations and the survival of the patients was found
(data not shown).
Microdeletions/Microamplifications
Due to the high variance of individual SNP intensities, aberrations
as small as one to three consecutive SNPs are easy to miss. The high
resolution of the SNP arrays, the small sample size, and the paired
sample approach enabled us to screen for small copy number changes
that have emerged in the tumor DNA. Therefore, we looked first for
monoallelic deleted SNP genome-wide. It is known that the remaining
allele is often inactivated by mutation or methylation. Only a very
small number of microdeletions could be retrieved using a threshold
of three consecutively deleted SNP loci detected at least in one single
case. No small amplifications could be detected. The genomic regions
that are affected by a monoallelic loss are listed in Table 3.
The deletion on chromosome 6 affects genes (PARK2 and PACRG )
that were also covered by a minimal overlapping region (Table 2) and
have an inferred function as TSGs.
Furthermore, the data set was screened for biallelic microdeletions.
We only found such completely deleted loci to harbor a single SNP
and to be located in exon-poor regions (gene deserts or very large first
introns, e.g., SNP_A-1513517, SNP_A-1509211, SNP_A-1507787,
SNP_A-1514639, SNP_A-1517606).
Validation of Gene Expression by qPCR
For validation of the microarray results, the mRNA expression of
the genes CSF1R (located on 5q), PARK2, and PACRG (both located
on 6q) was analyzed by qPCR. cDNA samples from 16 tumors and
matched normal tissues were available for this analysis.
As expected from the microarray data, the CSF1R relative tran-
script levels were up-regulated in 11 (69%) of 16 tumors (Figure 3).
The PACRG gene was completely lost in all of the 15 evaluable
cases. The PARK2 gene was down-regulated in 8 (57%) of 14 evalu-
able cases, whereby 5 of the 8 tumors showed a complete loss of
PARK2 expression.
The best concordance of qPCR and microarray data was found for
the PARK2 gene (50%, 7/14 cases) followed by CSF1R (38%, 6/16
cases) and PACRG (33%, 5/15 cases).
Validation of FOXP1 Expression by Immunohistochemistry
Large aberrations on 3p containing FOXP1 locus were found
by SNP array analysis in 91% of tumors. To validate this result,
immunohistochemical staining for FOXP1 was performed. In the
normal renal tissue, no concomitant nuclear and cytoplasmic FOXP1
Figure 2. Copy number and LOH profile of patient 154 in detail. (A) Copy number ratios in log2 scale between the tumor DNA and
unaffected DNA from the same patient. Each spot indicates a unique SNP locus corresponding to its genomic position aligned from
1pter (left) to Xqter (right). Each individual chromosome is coded in a different color. (B) SAS (=LOH) values for those SNP loci that were
informative (i.e., biallelic) in the control DNA. Markers that were not informative (monoallelic) in the healthy control DNA are not shown,
reducing the amount of data points by roughly two-thirds. In this case, losses in the copy number profile (on chromosomes 3p, 6p, and
8p) are always associated with LOH, so that a hypodiploid karyotype has to be assumed. Interestingly, the gain on chromosome 7 is not
accompanied by a shift in the allele ratio. We interpret this constellation as a sign of a mixed population of cells having either two
paternal and one maternal chromosome 7 and cells with two maternal and only one paternal chromosome 7.
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expression was noticed. Proximal tubuli showed an intense cytoplas-
mic FOXP1 expression, and distal tubuli showed an intense nuclear
expression. No or faint FOXP1 expression was noticed in glomeruli
and Henle loops.
In the analyzed tumors, an abnormal FOXP1 expression was
found in 18 (90%) of 20 cases: no expression in 3 cases (15%), a
weak expression in 4 cases (20%), and an aberrant expression in
11 cases (55%). Two cases showed an intense cytoplasmic FOXP1
expression (Figure 4).
In summary, our results for FOXP1 expression compared with
those of microarray analysis show a concordance of 85%.
Discussion
This study represents the first application of high-density Affy-
metrix 10K SNP genome-wide mapping arrays in simultaneous
screening for CNA and LOH in a larger cohort of patients with
cc-RCC. Previous studies showed that LOH and CNA analysis by
high-density SNP arrays is an efficient and rapidly available method
to detect changes in the DNA in different solid malignant neoplasms,
revealing candidate genes and loci possibly involved in tumor pro-
gression and inherited diseases [20–22].
Our analysis included tumor and matching normal DNA from
22 patients with cc-RCC with known clinicopathological and sur-
vival data. The samples showed very high genotyping efficiency with
SNP call rates up to 93%.
To analyze the arrays, we used a self-developed analysis algorithm
[18] with a higher sensitivity for the detection of microdeletions than
the Affymetrix standard software (CNAT 3.0). CNAT 3.0 assumes a
normal two-allele configuration, but tumor genomes often feature a
gain of a single copy leading to a 2:1 situation, which would render
biallelic (i.e., “AB”) calls difficult to interpret. The algorithm is de-
signed to reduce signal variation and therefore enabled us to detect
small, locally confined aberrations. In summary, the comparison of
the copy number profile obtained with our analysis approach with
the results derived from CNAT 3.0 showed good concordance in
general, but our generic approach yielded more stable profiles.
Frequent losses on chromosomes 3, 6q, 8p, 13q, 14q, and Xq and
gains on chromosomes 5q and 7 [10,23] were previously detected by
both CGH and array CGH. The most frequent large chromosomal
aberration found in our study was LOH due to a loss of one copy on
the short arm of chromosome 3, followed by a gain of 5q, and loss of
14q and chromosome 9.
Loss of heterozygosity without copy number aberration was no-
ticed on chromosomes 3, 6, and 7 (Figure 1, blue lines). Therefore,
there are two two-step possibilities: the first one is the doubling of
one allele AB to AAB followed by loss of one allele AAB to AA.
Another possibility is the loss of one allele AB in A, followed by dou-
bling of allele A in AA. A uniparental disomy for those cases is ex-
cluded because such an aberration should also be present in normal
tissue and we did not observe any case of uniparental disomy in the
nonmalignant tissues.
DNA copy number loss on 3p located in a minimal overlapping re-
gion comprising 3pter-3p21.31 was found in 91% of our cases of me-
tastasized and nonmetastasized RCC. Using CGH, Moch et al. [10]
detected losses on chromosome 3 in only 56% of nonmetastasized
cc-RCC. Because losses on 3p are known to be an early aberration in
renal carcinogenesis [4], this discrepancy not only could be unlikely
due to the fact that, in our study, metastasized tumors were also included
but also more likely due to the higher resolution of the SNP array.
Chromosome 3p harbors several other TSGs such as FOXP1, FHIT,
TUSC2, and MLH1 (Table 2) in addition to the well-described VHL
gene. The FOXP1 (forkhead box P1) gene at 3p14.1 is a member of
winged helix family of transcription factors that play an important
role in cellular transformation, differentiation, and proliferation.
FOXP1 may act as a TSG and is lost in several tumor types such as
endometrial or breast cancer [24,25]. In some types of lymphoma,
such as MALT lymphoma, FOXP1 is targeted by recurrent chromo-
some translocations, and its overexpression is associated with poor
prognosis [26]. We first studied the FOXP1 expression in normal renal
tissue and compared it with the FOXP1 expression in cc-RCC. In nor-
mal tissue, only nuclear or only cytoplasmic FOXP1 expression was
noticed; never both (Figure 4). In cc-RCC, an abnormal immunohis-
tochemical FOXP1 expression (concomitant nuclear and cytoplasmic
expression) or loss of FOXP1 expression (Figure 4) was found in 90%
of tumors.
Gains on 5q33-q35 were detected in 45% of our cases by SNP
microarray analysis. Gains of the CSF1R (colony-stimulating factor 1
Table 2. Frequent Large Copy Number Aberrations.
Aberration No. Events % Minimal Overlapping
Region
Candidate Genes*
3p− 20 91 3pter-3p21.31 FOXP1, FHIT, TUSC2, MHL1, VHL
5q+ 10 45 5q23.3-5qter CSF1R
14q− 8 36 14q23.3-14q.32.31 MLH3, FOXN3
9− 7 32 9pter-9qter CDKN2B, GAS1, DBC1
7q+ 7 32 7q11.21-7qter FZD9, MET, EPHA1
6q− 6 27 6q23.2-6q26 PLAGL1, LATS1, PACRG, PARK2
For each aberration found in more than 10% of the cases, number of events, percentage of events,
and the minimal overlapping region are indicated.
*Candidate genes were located in the minimal overlapping region and with an established/inferred
function as a TSG (case of losses) or oncogene (case of gains).
Table 3. Recurrent Small Regions of Monoallelic Loss.
Genomic Localization (I) Patients with More Than One SNP
Deleted (II)
Genes Disrupted (III) Patients with a Single SNP Deleted at the Genomic
Locus (IV)
Genes Potentially
Disrupted (V)
Chr 1: 239.498.674–240.013.390 18% FH, KMO, OPN3, CHML 32% RGS7, WDR64
Chr 4: 155.360.637–155.520.387 9% 5% DCHS2
Chr 6: 157.688.569–157.890.930 27% 14% ZDHHC14
Chr 6: 162.491.313–163.442.156 5% PARK2 5% PACRG
Chr 8: 13.155.237–13.746.870 5% 14% DLC1
Chr 9: 8.149.670–8.258.198 5% 5% PTPRD
The table compiles a number of recurrent small deletions that lead to a loss of a gene or parts of it.
Localizations (I) denote the mapping according to the 2007 freeze of the human genome (NCBI build 36.2). Column II indicates patients where, in at least three consecutive SNPs, a loss (ratios <1.0 in
the log2 scale) could be stated. These index deletions cover at least three SNPs but could be longer. Column III specifies genes that are affected by the index deletion. Column IV denotes patients with
deletion for at least one SNP in the region of the index deletion. Column V specifies genes that are located between the index deletion and the next SNP enclosing it and are potentially disrupted. The
deletion on chromosome 6 covers genes (PARK2 and PACRG ) with inferred function as tumor suppressor, which are also covered by a minimal overlapping region listed in Table 2.
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receptor) are the most frequent changes in this region, and mutations
of the CSF1R gene are supposedly involved in the progression of
cc-RCC [27].
An overexpression of CSF1R was detected by qPCR in 11 (69%)
of 16 tumors (Figure 3). The concordance between SNP microarray
data and qPCR was 38% (Table 4), suggesting that DNA-CNA is
only one pathway inducing an overexpression of CSF1R in cc-RCC.
In addition, gains in the region 5q22.1-23.2 were found in 27%
of our cases (Figure 1). A gain in this region could be the result of an
unbalanced translocation 3:5, which leads to a loss of 3p and dupli-
cation of 5q22~qter sequences in RCC. Nagao et al. [14] found that
patients with 3p loss and gain at 5q22.3-23.3 had a significantly bet-
ter disease-free survival than those who had a 3p loss without such a
gain. We could not detect a survival benefit for the patients with only
a 3p loss in our study (data not shown).
It has been shown that cc-RCC with LOH on chromosome 9 have
a higher risk of recurrence and a shorter tumor-specific survival
[28,29]. In the present study, aberrations on chromosome 9 were
Figure 4. Expression of FOXP1 by immunohistochemistry. FOXP1 nuclear and cytoplasmic expression in normal renal tissue (A; original
magnification, ×20); nuclear FOXP1 expression in cc-RCC (B; original magnification, ×20); lack of FOXP1 expression in cc-RCC (C; original
magnification, ×10); and abnormal concomitant membranous and nuclear FOXP1 expression in cc-RCC (D; original magnification, ×20).
Figure 3. Graphical representation of qPCR results. The mRNA expression of CSF1R was analyzed by qPCR in 16 matched pairs of
malignant and nonmalignant tissues. A twofold up-regulation (solid line) was considered as threshold for altered expression in tumor
samples. For one case (#154), no n-fold change could be calculated because the CSF1R expression level in the nonmalignant sample
was below the detection limit. This sample pair belongs to the group with altered expression.
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found in 7 (32%) of 22 tumors. Five of these seven patients are dead,
demonstrating the poor prognosis of cc-RCC with aberrations on
chromosome 9 (Table 1 and Figure 1).
As expected, the analysis with genome-wide SNP arrays revealed
additional small changes that were not yet detected by CGH or array
CGH. We used this high-resolution technology as a method to de-
tect loci crucial for tumor development in cc-RCC. Microamplifica-
tions were not found, but microdeletions leading to a monoallelic
loss of a gene or gene parts were occasionally encountered (Table 3).
On chromosome 1, we found microdeletions in 55% of the tumors.
An association between allelic imbalances on chromosome 1 and
cc-RCC is known; Zhao et al. [30] described LOH of HRPT2, located
at 1q25-q32 in various types of RCC including cc-RCC. In the pres-
ent study, a monoallelic deletion in a region comprising FH, KMO,
OPN3, and CHML on chromosome 1 was detected in four tumors
(Table 3). There are very small genes (7.07–63.5 kbp), and no SNP
was located directly in the genes. The deleted SNP are located at the
beginning and at the end of this small region containing these four
genes. There is currently very little information available linking these
genes to tumor formation or progression. Germline FH mutations are
associated with hereditary leiomyomatosis and renal cell cancer [31].
Microdeletions on chromosome 6 affecting PARK2 and PACRG
were found in 5% of the tumors. Mutations in both genes are known
to cause autosomal recessive juvenile parkinsonism [32,33]. Agirre
et al. [34] described that abnormal methylation and regulation of
PARK2 and PACRG may be involved in the pathogenesis of acute
lymphoblastic and chronic myeloid leukemia. We could show by
qPCR that PARK2 and PACRC are down-regulated in 57% (8/14)
and 100% (15/15) of cc-RCC, respectively, compared with the nor-
mal renal tissue (Figure 3), but the relevance of these genes in renal
carcinogenesis is still unknown. We also found by qPCR more tu-
mors showing down-regulation of PACRG and PARK2 as expected
after SNP microarray analysis, suggesting additional mechanisms,
such as methylation, involved in switching off both genes.
Microdeletions with potential gene disruption within or close to
the DLC1 (deleted in liver cancer 1) gene mapped to 8p22-p21.3 were
found in three cases (Table 3). This gene is deleted in primary hepa-
tocellular carcinoma, and studies done by Seng et al. [35] suggested
that this gene is a candidate TSG for human liver cancer as well as for
prostate, lung, colorectal, and breast cancers. Its role in renal carci-
nogenesis has still to be determined.
In conclusion, SNP arrays are an excellent tool not only to confirm
the previously described large chromosomal aberrations but also to
detect novel microdeletions in genes potentially involved in tumori-
genesis and progression of cc-RCC. Our results will need to be val-
idated on a larger patient cohort with known clinical outcome. The
significance of the described microdeletions in tumorigenesis and
progression of RCC remains to be proven.
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